The LeucoPatch device is designed to enhance wound healing by using a patient's own blood components (leucocytes, platelets, and fibrin) without any added reagents, targeted at hard-to-heal foot ulcers in diabetic patients.
A large-scale, international trial was conducted across 32 diabetic foot clinics in the UK, Denmark, and Sweden, comparing standard care to care with weekly application of LeucoPatch after a initial 4-week observation period.
Results showed that 34% of ulcers healed with LeucoPatch treatment compared to 22% with standard care, indicating a statistically significant improvement in healing and a faster recovery time, with similar rates of adverse events between both treatment groups.